Wednesday, April 3, 2019

Trovagene Inc. (TROV)

Updated early prostate cancer data demonstrates sustained PSA levels.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

• AACR Presentation. The company had the second presentation from a Phase 2 study of onvansertib in combination with Zytiga/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC), at the American Association for Cancer Research (AACR) annual meeting today, following the update from the acute myeloid leukemia (AML) trial (refer to the note published on April 2nd, 2019).
• Data Update in Prostate Cancer.  Onvansertib in combination with Zytiga/prednisone treatment achieved a reduction of prostate specific antigen (PSA) levels in 2 out of 6 mCRPC patients. The previous data reported at the Genitourinary Cancers Symposium (ASCO-GU, on February) showed reduced PSA levels, however levels were relapsed. The company plans to comm... 

Get full report on Channelchek desktop.

*Analyst certification and important disclosures included in full report.  NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.